flavonol glycoside

Flavonol glycoside tablets are an investigational botanical-derived pharmaceutical product developed by the Second Military Medical University of the People's Liberation Army of China (also known as the Naval Medical University). The drug is composed of flavonol glycosides, a sub-group of flavonoids known for their diverse biological activities, including potential lipid-lowering and antioxidant properties. It is currently being evaluated for the treatment of hypercholesterolemia. The therapeutic mechanism is believed to involve the modulation of lipid metabolism, although the specific molecular targets for this formulation have not been explicitly detailed in public clinical trial documentation. A Phase 1 clinical trial (CTR20171046) was conducted in China to assess the safety, tolerability, and pharmacokinetics of a single oral dose of the tablets in healthy adult volunteers.

Other names

flavonol glycoside tablets